Zacks Investment Research
17 Aug 2026, 17:46 UTC · 3h ago
Here is Why Growth Investors Should Buy Globus Medical (GMED) Now
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
17 Aug 2026, 17:46 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Globus Medical (GMED) is projected to have earnings per share (EPS) growth of 23.9% this year. — Strong projected earnings growth relative to the industry average typically drives positive price action for growth stocks.
+0.40Globus Medical's projected EPS growth of 23.9% significantly exceeds the medical device industry average of 10.9%. — Outperforming industry peers suggests a competitive advantage and higher attractiveness to institutional investors.
+0.30Globus Medical currently maintains an asset utilization (sales-to-total-assets) ratio of 0.59. — While a factual measure of efficiency, this specific ratio is a secondary metric with lower immediate price impact than earnings growth.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is recommended as a great growth pick with a top Zacks Rank and projected EPS growth that crushes the industry average.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
